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Selected literature
Part 1
The results of final analysis of the CREATE-X Phase 
III study were published in “New England Journal of 
Medicine” in June 2017. The study was designed to evalu-
ate the efficacy of capecitabine in postoperative treatment 
in patients with HER2-negative breast cancer, who did not 
achieve complete pathological response after preoperative 
treatment (invasive lesions/lymph node metastases). The 
study included 910 patients with HER2-negative breast 
cancer (I to IIIB) with no complete pathological response 
after preoperative chemotherapy (95% of patients re-
ceived anthracyclines given sequentially or concomitantly 
with taxanes, and 5% other chemotherapy regimens). 
Patients were randomly assigned 1:1 to 6–8 cycles of 
capecitabine (1250 mg/m2 of body surface twice a day 
on days 1–14 every 21 days) or standard postoperative 
treatment. Initially six to eight cycles of chemotherapy 
were used during postoperative treatment, with most pa-
tients receiving eight cycles. Neoadjuvant chemotherapy 
included at least four cycles with anthracyclines. Standard 
postoperative treatment included hormone therapy and 
radiotherapy, depending on the indications.
Three year disease-free survival (DFS) rates were 
82.8% and 73.9%, and five-year DFS rates 74.1% and 
67.6% in the capecitabine and control groups, respectively, 
which translates into statistically significant reduction in 
relative risk of recurrence (relapse/second cancer/death) 
by 30% (HR = 0.70, p = 0.01). Three-year overall survival 
(OS) rates were 94.0% and 88.9%, and five-year rates 
89.2% and 83.6% in the capecitabine and control groups, 
respectively, which translates into statistically significant 
reduction in relative risk of death by 41% (!) (HR = 0.59, 
p = 0.01). Subgroup analysis showed the greatest benefit 
from adjuvant treatment with capecitabine in patients with 
triple-negative breast cancer, with relative risk of death 
reduced by 48% (HR = 0.52, 95% CI 0.30–0.90). 
Adverse reactions were typical for capecitabine, with 
palmar-plantar erythrodysesthesia (PPE) observed in 
almost 75% of patients, including grade 3 PPE in 11% 
of patients.
Comment
We have known for a long time that obtaining a com-
plete pathological response (pCR) to neoadjuvant treat-
ment in breast cancer patients is an indicator of very good 
prognosis. On the other hand, the prognosis for complete 
cure in patients who have failed preoperative treatment 
(residual invasive cancer or metastatic lymph nodes in 
pathological examination) is still unfavourable. In adjuvant 
treatment of patients with HER2-positive or ER+ breast 
cancer, trastuzumab or hormone therapy are used, assum-
ing that they could improve prognosis of patients who did 
not achieve pCR after classic neoadjuvant chemotherapy. 
Currently, for patients with triple-negative breast cancer, 
who did not receive pCR after full preoperative treat-
ment, we do not have any options of adjuvant treatment. 
The final publication of the results of the CREATE-X 
study in the most important medical journal, the “New 
England Journal of Medicine”, is practically changing 
the standard of practice from today. Finally, we have 
an active therapeutic option with proven (IA) efficacy 
that decreases the relative risk of death by more than 
40% and relative risk of recurrence by 30%. Adjuvant 
treatment with capecitabine should be routinely used in 
patients with triple-negative breast cancer after failure of 
preoperative chemotherapy, and in patients with luminal 
B subtype this treatment should be considered. 
Source
1. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast 
cancer after preoperative chemotherapy. N Engl J Med. 2017; 376: 
2147–2159; http://www.nejm.org/doi/10.1056/NEJMoa1612645.
Adjuvant treatment with capecitabine of breast cancer patients after failure  
of preoperative chemotherapy
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Gemcitabine + capecitabine for adjuvant treatment of pancreatic cancer  
— full publication of ESPAC-4 results
The results of the ESPAC-4 study presented at 
ASCO meeting in June 2016 appeared in “The Lancet” 
in January 2017 as a full publication.
The ESPAC-4 study was a multicentre, open-label, 
randomised, controlled trial comparing gemcitabine in 
combination with capecitabine with gemcitabine alone 
for the adjuvant treatment of patients after macroscopi-
cally radical surgery (R0 or R1 resection) due to pancre-
atic adenocarcinoma. In total 732 patients in 92 hospitals 
in England, Scotland, Wales, Germany, France, and 
Sweden were included in the study between November 
2008 and September 2014. Patients received gemcitabine 
1000 mg/m2 in intravenous infusion on days 1, 8, and 15 in 
combination with oral capecitabine at a daily dose of 
1660 mg/m2 on days 1–21 of a 28-day cycle (n = 349) or 
gemcitabine alone in the same pattern (n = 358) as adju-
vant therapy. The treatment was administered for 24 weeks, 
i.e. six cycles. The primary endpoint of the study was overall 
survival. Secondary endpoints included: two-year and 
five-year survival rates and relapse-free survival.
The ESPAC-4 study showed statistically significant 
improvement of overall survival in the capecitabine plus 
gemcitabine arm [an increase in median OS by 2.5 months 
from 25.5 to 28 months; HR for OS 0.82 (95% CI 0.68– 
–0.98), p = 0.032]. There was also an increase of the 
five-year survival rate by 12.5% (from 16.3% to 28.8%). 
The greatest benefit was observed in R0 patients. Median 
survival in patients after R0 resection was 39.5 months in 
the combination group versus 27.9 months in the gemcit-
abine alone group. In patients undergoing R1 resection 
these medians were 23.7 months (gemcitabine + capecit-
abine) and 23.0 months (gemcitabine), respectively. 
12-month and 24-month survival rates were 84.1% and 
53.8%, respectively, in the combination arm and 80.5% 
and 52.1% in the arm with gemcitabine alone. Toxic-
ity during combination therapy was markedly higher, 
although manageable by means of recognised and avail-
able management methods. It did not have a significant 
negative impact on patients’ quality of life. According to 
the authors, the combination of gemcitabine and capecit-
abine should be the treatment of choice in patients after 
pancreatic cancer resection.
Comment
The results of the ESPAC-4 study have significantly 
altered the standard of care for postoperative patients 
with pancreatic adenocarcinoma and indicate a pos-
sible improvement of prognosis. Significant efficacy 
of postoperative combined chemotherapy is reported 
primarily in patients after microscopically radical resec-
tion (R0). This observation confirms the importance of 
good qualification of patients and of conducting surgi-
cal treatment in specialised, extensively experienced 
surgical centres. Since September 2016 capecitabine has 
been reimbursed in combination with gemcitabine in 
the postoperative treatment of patients with pancreatic 
adenocarcinoma within the chemotherapy catalogue.
Sources
1. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant 
gemcitabine and capecitabine with gemcitabine monotherapy in 
patients with resected pancreatic cancer (ESPAC-4): a multicentre, 
open-label, randomised, phase 3 trial. Lancet. 2017; 389: 1011–1024, 
http://dx.doi.org/10.1016/S0140-6736(16)32409-6; http://www.thelan-
cet.com/pdfs/journals/lancet/PIIS0140-6736(16)32409-6.pdf.
2. Deplanque G, Demartines N. Comment. Pancreatic cancer: are more 
chemotherapy and surgery needed? Lancet. 2017; 389: 985–986; 
http://dx.doi.org/10.1016/S0140-6736(17)30126-5; http://www.sci-
encedirect.com/science/article/pii/S0140673617301265.
3. Neoptolemos JP, Palmer DH, Ghaneh P, et al. ESPAC-4: A multicenter, 
international, open-label randomized controlled phase III trial of adju-
vant combination chemotherapy of gemcitabine (GEM) and capecit-
abine (CAP) versus monotherapy gemcitabine in patients with resected 
pancreatic ductal adenocarcinoma. J Clin Oncol. 2016; 34 (suppl; 
abstr LBA4006); http://meetinglibrary.asco.org/content/162546-176.
4. Obwieszczenie z dnia 19 sierpnia 2016 r. w sprawie wykazu refun-
dowanych leków, środków spożywczych specjalnego przeznaczenia 
żywieniowego oraz wyrobów medycznych na 1 września 2016 r. 
Załącznik do obwieszczenia Ministra Zdrowia z dnia 19 sierpnia 2016 
r. (poz. 79). Wykaz refundowanych leków, środków spożywczych 
specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych 
na dzień 1 września 2016 r.; http://www.mz.gov.pl/wp-content/uplo-
ads/2016/08/zalacznik-do-obwieszczenia-2.pdf.
New standard of zoledronic acid use in patients with bone metastases from solid 
tumours
In January 2017 “JAMA” and “JAMA Oncology” 
published the results of two randomised clinical trials 
evaluating the efficacy of a new zoledronic acid (ZOL) 
treatment regimen in patients with bone metastases 
from cancers. For many years, administration of ZOL 
every 3–4 weeks has been well established as a prophy-
laxis of skeletal related events (SRE) in patients with 
advanced solid tumours with bone lesions, which 
is according to a registered label. ZOL given every 
3–4 weeks reduces pain and decreases the incidence of 
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SRE including fractures, spinal cord compression, and 
the need for surgery or irradiation by 25 to 40%. Zole-
dronic acid, a bisphosphonate of the third generation, 
similarly to other bisphosphonates, has side effects, of 
which osteonecrosis of the jaw, impaired renal function, 
and hypocalcaemia are the most serious. For many 
years the possibility of administering this drug at longer 
intervals has been consdidered. Recently published 
results of clinical trials concern a new regimen for the 
use of this drug, i.e. three-month intervals instead of 
four weeks. The results of these studies confirm the 
initial observations regarding the possibility of reduc-
ing the frequency of zoledronic acid infusions as part 
of SRE prophylaxis in the ZOOM study published in 
“The Lancet” in 2013 and endorse the new standard of 
SRE prophylaxis in patients with bone metastases in the 
course of advanced cancer based on administration of 
zoledronic acid with three-month intervals.  
The study published by Himelstein et al. answers 
the question of whether the use of ZOL in patients with 
bone metastases due to solid tumours in a three-month 
regimen for two years was no less effective than ZOL 
administered every four weeks. In an open-label, ran-
domised study 1822 patients participated with general-
ised breast cancer (n = 855), prostate cancer (n = 689), 
and multiple myeloma (n = 278), with a median age of 
65 years. In total 795 patients completed the study; in 
29.5% of patients receiving ZOL every four weeks and 
28.6% of patients receiving ZOL every 12 weeks at least 
one SRE occurred within two years after randomisation. 
The SRE ratio did not significantly differ between the 
two study groups, and the pain index, performance pa-
rameters, incidence of osteonecrosis, and renal dysfunc-
tion also did not differ significantly between groups. The 
mortality rate due to bone complications was similar 
in both groups; however, the so-called bone turnover 
(expressed as C-terminal telopeptide concentration) was 
higher in the group receiving ZOL every three months.
The prospective, multicentre, double-blind, phase 
III, randomised clinical trial OPTIMIZE-2 was designed 
to compare efficacy of ZOL used at 4- and 12-week 
intervals for one year. The study involved 416 patients 
(median age 59.2 years) with bone metastases due to 
breast cancer, who had previously received at least 
nine doses of zoledronic acid or pamidronic acid within 
10–15 months. In total 203 patients received ZOL every 
12 weeks, 200 patients received ZOL every four weeks, 
and 13 patients received placebo. After a one-year fol-
low-up period, the incidence of SRE in both groups was 
not significantly different (22.0% in the group receiving 
ZOL every four weeks versus 23.2% in the group receiv-
ing ZOL every 12 weeks), similarly to time to first SRE 
occurrence (HR 1.06; 95% CI, 0.70–1.60; p = 0.79). The 
mortality rate associated with bone complications was 
0.46 in a group receiving ZOL every four weeks and 0.5 in 
a group receiving ZOL every 12 weeks, respectively. The 
safety profile of ZOL in both groups was similar, 95.5% 
of patients in a group receiving ZOL every four weeks 
had at least one adverse event (n = 189), and in a group 
receiving ZOL every 12 weeks it was 93.5% (n = 189). 
Comment
Published results of clinical trials confirm that the ef-
ficacy of zoledronic acid administered at 12-week inter-
vals is no less than the efficacy of this drug at four-week 
intervals, with comparable tolerability and safety profile. 
These observations should serve as a basis for changing 
the current ZOL use standard regimen with intervals of 
3–4 weeks to a schedule with 12-week intervals.
Sources
1. Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued treatment 
effect of zoledronic acid dosing every 12 vs 4 weeks in women with 
breast cancer metastatic to bone. The OPTIMIZE-2 randomized 
clinical trial. Jama Oncol. 2017; 3: 906–912; doi:10.1001/jamaon-
col.2016.6316; http://jamanetwork.com/journals/jamaoncology/fullar-
ticle/2598744?utm_campaign=articlePDF&utm_medium=articlePD-
Flink&utm_source=articlePDF&utm_content=jamaoncol.2016.6316.
2. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval 
vs standard dosing of zoledronic acid on skeletal events in patients with 
bone metastases. A randomized clinical trial. JAMA 2017; 317: 48–58; 
doi:10.1001/jama.2016.19425; http://jamanetwork.com/journals/jama/ful-
larticle/2595526?utm_campaign=articlePDF&utm_medium=articlePD-
Flink&utm_source=articlePDF&utm_content=jama.2016.19425.
3. Amadori D, Aglietta M, Alessi B, et al. Efficacy and safety of 12-weekly 
versus 4-weekly zoledronic acid for prolonged treatment of patients 
with bone metastases from breast cancer (ZOOM): a phase 3, open-la-
bel, randomised, non-inferiority trial. Lancet Oncol. 2013; 14: 663–670; 
doi: 10.1016/S1470-2045(13)70174-8; http://www.sciencedirect.
com/science/article/pii/S1470204513701748.
Pembrolizumab in second-line treatment of patients with bladder cancer 
— a significant improvement of overall survival and a positive impact on quality  
of life (phase 3 KEYNOTE-045 study)
Advanced transitional cell carcinoma (TCC) remains 
a malignancy of poor prognosis and treatment options 
in subsequent lines, after exhaustion of efficiency of 
first-line platinum-based regimens, are limited. The 
results of the phase 3 KEYNOTE-045 study published 
in “New England Journal of Medicine” in February 
2017 show improvement of prognosis in patients treated 
with pembrolizumab.
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The KEYNOTE-045 (NCT02256436) study was an 
open, international phase III randomised clinical trial, 
involving patients with advanced urothelial cancer with 
recurrence or progression of disease following prior 
platinum-based chemotherapy (n = 542). Patients were 
randomly assigned to receive pembrolizumab 200 mg 
every three weeks (n = 270) or chemotherapy with pa-
clitaxel (175 mg/m2), docetaxel (75 mg/m2), or vinflunine 
(320 mg/m2) every three weeks (n = 272) based on inves-
tigator choice. Primary endpoints of the study were overall 
survival (OS) and progression-free survival (PFS), assessed 
in the whole group and among patients with PD-L1-posi-
tive tumours (at least 10%; the ratio of PD-L1-positive 
tumour cells and infiltrating immune cells to all cells in the 
tumour was assessed). Secondary endpoints were objective 
response rate, duration of response, and safety.
In the total study population (regardless of PD-L1 ex-
pression level) the use of pembrolizumab was associated 
with a significant reduction of relative risk of death by 
27% (median OS: 10.3 months for pembrolizumab versus 
7.4 months for chemotherapy; HR = 0.73; p = 0.002). In 
the PD-L1-positive population the use of pembrolizumab 
was associated with a reduction of relative risk of death by 
43% (median OS: 8.0 months for pembrolizumab versus 
5.2 months for chemotherapy, HR = 0.57, p = 0.005). 
The use of immunotherapy resulted in significantly high-
er objective response rate (21.1% vs. 11.4%; p = 0.001). 
There were no significant differences in progression-free 
survival between the study and control groups.
Immunotherapy was better tolerated than chemo-
therapy. At least one adverse event was observed in 
60.9% of patients undergoing immunotherapy and 
90.2% of patients receiving chemotherapy, and severe 
adverse events occurred in 15% and 50% of patients, 
respectively. The most frequently observed adverse 
events related to immunotherapy (of any grade of in-
tensity) include pruritus (in 19.5% of patients), fatigue 
(13.9%), and nausea (10.9%).
During the 2017 Genitourinary Cancers Symposium 
in Orlando, the results of the KEYNOTE-045 study were 
presented regarding patients’ quality of life assessed us-
ing the EORTC QLQ-C30 questionnaire. At baseline 
the overall health status and quality of life were similar 
in both groups. In the pembrolizumab group the values 
were stable at up to 15 weeks of treatment, and in the 
chemotherapy group they deteriorated at the same time. 
Comparing to chemotherapy, use of pembrolizumab 
was associated with long-term maintenance of good 
quality of life. 
Comment
The results of KEYNOTE-045 study represent 
a breakthrough in second-line treatment of patients 
with advanced urothelial bladder cancer as such results 
confirm the significant improvement of prognosis by im-
munotherapy. In this study, pembrolizumab significantly 
prolonged overall survival compared to chemotherapy 
with a much better safety profile. As with other can-
cers, there was no significant effect of anti-PD1 im-
munotherapy on progression-free survival compared 
to standard treatment.
Currently, in  the US three other drugs belonging to 
the group of checkpoint inhibitors are registered for the 
treatment of advanced bladder cancer patients: atezoli-
zumab, durvalumab and nivolumab. They received FDA 
marketing authorisation based on the results of phase 
II studies. In 2017 EMA has approved pembrolizumab 
and nivolumab for second line treatment of urothelial 
bladder cancer. 
Sources
1. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line 
therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 376: 
1015–1026; doi: 10.1056/NEJMoa1613683.
2. Vaughn DJ, Bellmunt J, de Wit R, et al. Health-related quality of life 
(HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investi-
gator-choice chemotherapy for previously treated advanced urothelial 
cancer. J Clin Oncol. 2017; 35 (suppl 6S; abstr 282).
ASCO and CCO recommendations on the use of bisphosphonates in the adjuvant 
treatment of patients with breast cancer
On 6 March 2017 the JCO published new evi-
dence-based recommendations from the American So-
ciety for Clinical Oncology (ASCO) and CCO (Cancer 
Care Ontario) on the use of bisphosphonates and other 
bone turnover modulators for the adjuvant treatment of 
breast cancer patients, prepared by the authors based 
on a review of available literature.
Based on review, it was found that the use of bi-
sphosphonates in adjuvant therapy reduces the risk 
of bone metastases and the risk of death from breast 
cancer in postmenopausal patients. In almost all stud-
ies included in the review, patients received systemic 
treatment at the same time. It was noticed that the 
absolute benefit from using bone modulators is greatest 
in patients with a higher risk of recurrence. In most of 
the reviewed studies zoledronic or clodronic acid was 
used, so the data on the use of other bisphosphonates 
are very limited. Denosumab has been shown to reduce 
the risk of fractures, with no data on its impact on 
long-term survival. 
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According to the aforementioned guidelines for post-
menopausal patients eligible for systemic adjuvant treat-
ment after breast cancer surgery zoledronic acid should be 
considered, if possible, administered every six months or 
oral clodronic acid administered every day. The decision 
regarding implement this procedure should be based on 
a discussion with the patient about the potential benefits 
and risks and taking into account patient and disease char-
acteristics, including recurrence risk. Prior to use of these 
drugs, the risk of osteonecrosis of mandible and/or maxilla 
and deterioration of kidney function should be assessed, 
and any changes in the oral cavity and changes requiring 
dental treatment should be cured before treatment.
Comment
Meta-analysis, based on review of individual cases of 
more than 22,000 patients participating in seven clini-
cal trials, published in “The Lancet” in 2015 has shown 
that the benefit of bisphosphonates in adjuvant therapy 
is independent of the bisphosphonate used (clodronic, 
ibandronic, zoledronic acid). Considering the benefits 
from complementary use of bisphosphonate in postmen-
opausal breast cancer patients, including the reduction 
of risk of recurrence in bones, death from breast cancer, 
and the prevention of osteoporosis and its complications 
(including fractures), the use of this group of drugs seems 
justified. Taking all of the above data into account, the 
optimum, least debilitating form of bisphosphonate use 
appears to be either using 4 mg of zoledronic acid in 
intravenous infusions every six months for 3–5 years or 
oral clodronic acid 1600 mg daily for 2–3 years.  
Sources
1. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant 
bisphosphonates and other bone-modifying agents in breast cancer: 
A Cancer Care Ontario and American Society of Clinical Oncology 
Clinical Practice Guideline. J Clin Oncol. 2017; 35: 2062–2081; doi: 
10.1200/JCO.2016.70.7257.
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant 
bisphosphonate treatment in early breast cancer: meta-analyses of 
individual patient data from randomised trials. The Lancet. 2015; 
386: 1353–1361; http://thelancet.com/pdfs/journals/lancet/PIIS0140-
6736(15)60908-4.pdf.
Thrombocytosis as a predictor of cancer — results of prospective cohort studies, 
published in “The British Journal of General Practice”
In May 2017 “The British Journal of General Practice” 
published the results of a prospective cohort study based 
on an analysis of available evidence from clinical practice 
from the years 2000–2013 regarding the risk of malignant 
neoplasia in people with thrombocytosis (> 400,000/µL). 
The incidence of cancers within one year was compared in 
two groups: 40,000 patients at the age of at least 40 years 
with thrombocytosis and 10,000 patients with normal level 
of platelets. Additional analyses included the assessment 
of cancer risk according to gender, age, platelet count, and 
tumour location. In the published analysis, malignant dis-
ease was diagnosed in 11.6% of men with thrombocytosis 
(1098 out of 9435, 95% CI 11.0–12.3) and in 4.1% without 
thrombocytosis (106 out of 2599, 95% CI 3.4–4.9), and in 
6.2% of women with thrombocytosis (1355 out of 21,826, 
95% CI 5.9–6.5) and 2.2% without thrombocytosis (119 out 
of 5370, 95% CI 1.8–2.6). The risk of cancer increases to 
18.1% in men and 10.1% in women if no further reduction 
in thrombocytosis is observed in a subsequent blood test after 
six months. In people with thrombocytosis, the most com-
monly diagnosed cancer is lung cancer and colorectal cancer. 
In one third of people with thrombocytosis who develop 
these cancers, there are no signs of active malignant disease.
Comment
Thrombocytosis is a phenomenon often associated 
with advanced cancer, but its role as an early marker of 
malignant disease has not been clearly proven to date. 
Based on a large, prospective population study, strong 
arguments have been obtained for increased oncological 
alertness in healthy subjects who experience thrombo-
cytosis (> 400,000 PLT/µL) in routine laboratory tests, 
especially if the elevated values persist in subsequent test, 
performed after six months. Among men with thrombo-
cytosis the incidence of lung cancer is clearly increased 
from 14% to 23% and colorectal cancer from 14% to 
18% as well as cancers of upper gastrointestinal tract, as 
compared to the general population of men in the UK. 
Contrary to this, in women the incidence of colorectal 
cancer increases from 11% to 21%, and lung from 12% 
to 14%, as well as ovarian cancer. Prostate cancer and 
breast cancer are relatively less common in individuals 
with thrombocytosis than in the general population.
The results of this study should provide the basis for 
increased oncological alertness, especially for primary 
care physicians, and faster referral to prophylactic 
treatment of patients with thrombocytosis, especially if 
it persists for at least six months.
Source
1. Bailey SE, Ukoumunne OC, Shephard EA, Hamilton W. Clinical rele-
vance of thrombocytosis in primary care: a prospective cohort study of 
cancer incidence using English electronic medical records and cancer 
registry data. British Journal of General Practice. 2017; 67: e405–e413; 
bjgp17X691109 DOI: 10.3399/bjgp17X691109; https://www.ncbi.nlm.
nih.gov/pubmed/28533199.
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Correlation between obesity and morbidity and mortality due to cancer — a review 
published in “British Medical Journal” in February 2017
Obesity is becoming the biggest health problem 
in the world and is responsible for numerous serious 
diseases, including cardiovascular diseases and type 
2 diabetes. Over the past 40 years the incidence of 
obesity worldwide has doubled in women and increased 
three-fold in men. An increasingly explored and dis-
cussed topic is the relationship between morbidity and 
mortality due to malignant neoplasms and obesity. Pre-
vention and treatment of obesity can reduce not only the 
incidence and mortality rates of cardiovascular diseases 
or diabetes, but also of malignancies. 
The authors reviewed 204 systematic reviews and 
meta-analyses dedicated to assessing the association be-
tween obesity and morbidity and mortality due to 36 ma-
lignancies. PubMed, Embase, and Cochrane databases 
were searched for meta-analyses and systematic reviews 
of the association between obesity-related parameters 
and development of cancers or death from malignant 
neoplasms using a previously prepared algorithm. The 
obesity parameters included body mass index (BMI), 
waist circumference, hip circumference, body weight, 
weight gain, and weight loss after bariatric surgery. 
In total 204 meta-analyses assessed the relationship 
between obesity parameters (mentioned above) and 
incidence (n = 196) and mortality (n = 8) due to cancers 
of 36 anatomical locations.
Based on the review, the authors noted that the 
relationship between obesity and the occurrence of vari-
ous cancers has been investigated previously, with 11 of 
them being fully confirmed. They are primarily tumours 
of the gastrointestinal tract (GI) and hormone-related 
cancers in women. BMI increase was associated with 
a higher incidence of esophagogastric junction (EGJ) 
carcinoma, colon and rectal cancer in men, cancers of 
the biliary tract, pancreatic carcinoma, endometrial 
cancer in premenopausal women, renal-cell cancer, 
and myeloma. Weight gain and waist-to-hip circumfer-
ence ratio were associated with a higher risk of breast 
cancer in postmenopausal women who had never used 
hormone replacement therapy (HRT) and endometrial 
cancer. The increase in cancer risk for each weight 
gain by 5 kg/m2 of BMI ranged from 9% (relative risk 
1.09, 95% CI: 1.06–1.13) for rectal cancer in men to 
56% (1.56, 95% CI 1.34–1.81) for biliary tract cancer. 
The risk of breast cancer in postmenopausal women 
who had never used HRT increased by 11% for every 
5 kg of body weight gain during adulthood (1.11, 95% 
CI 1.09–1.13) and the risk of endometrial carcinoma 
by 21% for each increase in waist-to-hip circumference 
ratio by 0.1 (1.21, 95% CI 1.13–1.29). The other five 
links were supported by strong evidence for the use 
of specific methods of measuring obesity: weight gain 
with colorectal cancer, incr eased BMI with biliary tract 
cancer, gastric cardia, and ovarian cancer; and the as-
sociation with mortality due to myeloma. 
Comment
Obesity and associated risks of other diseases are 
becoming a leading health problem worldwide. Evidence 
for the link between obesity and morbidity and mortal-
ity due to cancers may facilitate future screening of 
individuals at increased risk for morbidity/mortality, in 
whom implementation of primary and secondary preven-
tion may be attempted. This knowledge also constitutes 
a strong argument in the fight against obesity, being an 
increasingly important health problem. 
Source
1. Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at 
major anatomical sites: umbrella review of the literature. BMJ. 2017; 
356: j477; http://www.bmj.com/content/356/bmj.j477.
